Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short term Debt (2016 - 2021)

Historic Short term Debt for ImmunityBio (IBRX) over the last 8 years, with Q3 2021 value amounting to $8.7 million.

  • ImmunityBio's Short term Debt rose 54137.17% to $8.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $8.7 million, marking a year-over-year increase of 54137.17%. This contributed to the annual value of $14.8 million for FY2020, which is 295308.64% up from last year.
  • As of Q3 2021, ImmunityBio's Short term Debt stood at $8.7 million, which was up 54137.17% from $16.7 million recorded in Q2 2021.
  • ImmunityBio's Short term Debt's 5-year high stood at $17.8 million during Q1 2021, with a 5-year trough of $486000.0 in Q4 2019.
  • Over the past 5 years, ImmunityBio's median Short term Debt value was $2.1 million (recorded in 2017), while the average stood at $4.5 million.
  • In the last 5 years, ImmunityBio's Short term Debt crashed by 7134.43% in 2019 and then soared by 295308.64% in 2020.
  • ImmunityBio's Short term Debt (Quarter) stood at $2.4 million in 2017, then decreased by 28.23% to $1.7 million in 2018, then tumbled by 71.34% to $486000.0 in 2019, then skyrocketed by 2953.09% to $14.8 million in 2020, then crashed by 41.39% to $8.7 million in 2021.
  • Its Short term Debt stands at $8.7 million for Q3 2021, versus $16.7 million for Q2 2021 and $17.8 million for Q1 2021.